Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
TerminatedPhase 3Results postedLast updated 16 December 2024
What this trial tests
Phase 3 trial testing Tozinameran - Standard dose in COVID-19 in 13 participants. Terminated before completion.
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
SARS-CoV-2 Specific Immunoglobulin (Ig)G Antibodies at 28-days Post Booster VaccinationPrimary· 28-days post booster vaccination.
Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using the commercial Euroimmun S1 IgG ELISA. Data will be reported as binding antibody units/mL and presented as geometric mean concentration and 95% confidence intervals
Group
Value
95% CI
Standard Pfizer-BioNTech Booster Group
1927.1
1665.4 – 3043.5
Fractional Pfizer-BioNTech Booster Group
13707.2
13707.2 – 13707.2
Standard Elasomeran Booster Group
5118.6
3837.6 – 8756.9
Fractional Elasomeran Booster Group
5908.7
4926 – 6741.3
Adverse events — posted to ClinicalTrials.gov
Time frame: 7 days post vaccination.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose in adults, who have previously received either Pfizer-BioNTech or AstraZeneca as their primary doses.
Both fractional and standard doses of Pfizer-BioNTech or Moderna will be tested.
The trial intervention will be given in line with Australian Technical Advisory Group on Immunisation (ATAGI) recommendations for booster vaccine doses which allows booster doses from 5 months onwards . There will be a total of 8 groups, with 100 individuals of even spread of participants above and below 50 years in each group. The trial will be single site, based at Royal Children's Hospital, Melbourne, Australia
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Other Murdoch Childrens Research Institute trials
Trials by the same sponsor.
NCT07251790 — Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study
· NA
· not yet recruiting
NCT07136584 — SOS for Caregiver Wellbeing
· NA
· recruiting
NCT06686446 — Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial
· NA
· terminated
NCT06992141 — A Strep Throat Controlled Human Infection Trial in Healthy Adults
· EARLY_PHASE1
· completed
NCT06186141 — Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone
· Phase 4
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Murdoch Childrens Research Institute
Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05228730.